- 1 Comprehensive analysis of key m6A RNA modification-related
- 2 genes and immune infiltrates in hypertrophic cardiomyopathy
- 3 Xia Hu<sup>1</sup>, Bo Liang<sup>2</sup>
- 4 1. Shanghai Jiaotong University, Shanghai, China
- 5 2. Xinqiao Hospital ,Chongqing, China
- 6 Correspondence: Dr. Bo Liang
- 8 Abstract

- 9 Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease.
- 10 We performed a comprehensive analysis to construct the correlation of m6A and
- immune in HCM. Two HCM datasets (GSE141910 and GSE160997) and m6A-
- 12 related regulators were obtained from GEO and published articles, respectively.
- 13 Differentially expressed m6A-related regulators were obtained. Random forest model
- and nomogram were conducted to assess the risk of HCM, and finally, the m6A
- 15 subtype was constructed. Functional enrichment analysis was conducted. Protein-
- protein interaction network of differentially expressed genes between m6A subtypes
- 17 was performed. Furthermore, we constructed the Hubgene-chemical network,
- Hubgene-microRNA network, and Hubgene-transcription factor network of the top 10
- 19 hubgenes. Additionally, the immune subtype and hubgene subtype were constructed.
- 20 PCR was performed to validate the m6A-related regulators. We obtained 20 m6A-
- 21 related regulators in HCM. Among them, 8 m6A-related regulators differentially
- 22 expressed (YTHDC1, HNRNPC, and FMR1 were up-regulated while YTHDC2, FTO,
- WTAP, IGF2BP2, and IGF2BP3 were down-regulated). FTO, FMR1, IGF2BP3,
- 24 YTHDC1, and IGF2BP2 were the top 5 important m6A-related regulators and were
- used to conduct the nomogram. We obtained 329 differentially expressed genes in
- 26 m6A subtype and these genes enriched HCM-related processes and pathways.
- 27 Furthermore, we constructed the Hubgene-chemical network, Hubgene-microRNA

28 network, and Hubgene-transcription factor network of the top 10 hubgenes (NFKBIA, 29 NFKB1, PSMA3, PSMC4, PSMA2, PSMA4, PSMD7, PSMD10, PSMD8, and 30 PSMA6). And then we constructed an immune subtype based on the immune cell 31 infiltration levels and hubgene subtype based on the expression of the top 10 32 hubgenes. Finally, we verified the main results through experiments. In conclusion, 33 we built a nomogram and identified 8 m6A-related regulators and 10 hubgenes, which 34 were prominently associated with HCM. We found that m6A and the immune system 35 may play a crucial role in the HCM. Accordingly, those genes and pathways might 36 become therapeutic targets with clinical usefulness in the future. 37 38 39 40 **Keywords**: Hypertrophic cardiomyopathy; Epigenetics; N6-methyladenosine; 41 Immune; Bioinformatics

## 1. Introduction

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Hypertrophic cardiomyopathy (HCM) is the commonest primitive inherited disease of the myocardium[1], with an autosomal dominant pattern of inheritance and a worldwide prevalence of approximately one in 500 adult subjects[2, 3]. HCM is defined principally by left ventricular hypertrophy without increased cardiac afterload or another underlying pathophysiological etiology, and causes heart failure at any age[4]. A clinical diagnosis of HCM in adults can be established by imaging with 2D echocardiography or cardiovascular magnetic resonance[5]. According to the latest guidelines[2, 3], pharmacological therapy for HCM patients includes non-selective drugs such as β-blockers, cardiac-selective calcium antagonists, and disopyramide, to be used in symptomatic patients with obstruction of the left ventricular outflow tract. Current drugs are unable to address the pathophysiological mechanisms of left ventricular dysfunction in HCM and are not, therefore, effective in preventing arrhythmias or slowing down disease progression in HCM patients[1]. Novel allosteric inhibitors of myosin are being developed and clinically validated, specifically targeting HCM-related pathophysiological mechanisms, such as myocardial hypercontractility and altered energetics[6]. However, HCM is a heterogeneous disease that involves numerous sarcomere-independent morphological features, suggesting that the precise mechanisms of HCM have not been fully elucidated. Epigenetic dysregulation is crucial for the pathological development of cardiovascular diseases[7, 8]. N6-methyladenosine (m6A) is the most common post-transcriptional modification of mRNA[9] and has recently attracted great attention. m6A influences a series of biological functions in cardiovascular diseases. m6A RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium[10] and modulates endothelial atherogenic responses to disturbed flow in mice[11]. Agerelated differences in m6A in response to acute myocardial ischemia/reperfusion injury[12] and m6A might play important roles in blood pressure regulation[13]. m6A

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

modification effectively improves the cardiac function and decreases the infarct size in acute myocardial infarction through tricarboxylic acid cycle-based metabolic reprogramming[14] and promotes miR-133a repression during cardiac development and hypertrophy via IGF2BP2[15]. In heart failure, FTO-dependent cardiac m6A methylome plays a functional importance in cardiac contraction[16] and m6A might be an interesting target for the rapeutic interventions [17]. However, the role of m6A in HCM is largely unknown. m6A RNA modification acts as a novel regulator in both innate and adaptive immune response[18, 19]. In acute myocardial infarction and aortic dissection, m6A is closely connected to immune cell infiltration[20, 21]. Previous study showed that the changes in the immune system engage in the HCM mechanisms[22, 23] and the systemic immune-inflammation index is a significant risk factor for all-cause mortality in HCM patients[24]. All these evidence supports immune response has a significant impact on the HCM biology and outcome. However, the crosstalk between m6A and immune response in HCM is poorly understood. In this study, we comprehensively evaluated the expression of m6A-related regulators and immune cell infiltration in HCM patients from two independent cohorts, constructed random forest model and nomogram, and further identified m6A and immune subtype (Figure 1). 2. Methods 2.1 Data collection Two HCM datasets from GEO, namely GSE141910 and GSE160997[25], were obtained though the GEOquery package and details are shown in Table 1. All samples were pooled after removing batch effects (Figure S1), as descried previously[26, 27]. In addition, m6A-related regulators were extracted based on published literature. 2.2 m6A-related regulators in HCM The chromosomal locations of m6A-related regulators were visualized using the RCircos package and the differential expression levels of m6A-related regulators between HCM patients and the controls were analyzed using the *limma* package.

111

121

99 Finally, linear regression analysis was used to explore the correlation between m6A 100 writers and m6A erasers. 2.3 Construction of random forest model and nomogram 102 Random forest is a compositionally supervised learning method that can be viewed as 103 an extension of decision tree[28]. We divided patients with HCM into the training 104 cohort and the validation cohort by 7:3, and selected candidate m6A regulators from 105 all m6A-related regulators to predict the occurrence of HCM. We built the random 106 forest model in the training cohort with ntrees = 500, and then analyzed the 107 importance of m6A-related regulators and evaluated the model with residual analysis 108 and ROC curves on both training and validation cohorts. 109 We constructed a nomogram based on the top 5 candidate m6A regulators using the 110 rms package to predict the prevalence of HCM patients. Calibration curve, decision curve analysis, and ROC curve were conducted to evaluate the nomogram, as 112 described previously[29, 30]. Finally, we explored the correlation between top 5 113 candidate m6A regulators and immune-related cell types. 114 2.4 m6A subtype construction 115 We used the Consensus Cluster Plus package [31] to identify the membership and 116 number of clusters in datasets based on the expression of the top 5 m6A-related 117 regulators. Then individuals were clustered into corresponding clusters. We further 118 analyzed the expression of the top 10 hubgenes in corresponding clusters. The 119 differentially expressed genes among clusters were analyzed using the *limma* package 120 with a threshold of adjusted P < 0.05 and  $|\log_2 \text{Fold Change}| > 2$  and the ggplot2 package[26] was used to visualization. 122 We used the *clusterProfiler* package[32] to perform gene ontology (including cellular 123 component, molecular function, and biological process) and Kyoto Encyclopedia of 124 Genes and Genomes enrichment analysis on differentially expressed genes with a 125 threshold of P < 0.5 and false discovery rate < 0.05. The specific Kyoto Encyclopedia 126 of Genes and Genomes terms were visualized through the *Pathview* package[33]. 127 Gene sets of c2.cp.v7.4.symbols.gmt, which are curated from various sources,

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

including online pathway databases and the biomedical literature, were downloaded from Molecular Signatures Database[34] as background for gene set enrichment analysis[35]. Adjusted P < 0.05 was considered statistically significant. The STRING database[36] was used for protein-protein interaction analysis of differentially expressed genes, and those genes with a score greater than 0.6 were selected for later analysis. The cytoHubba plugin[37] in Cytoscape[38] was used to functionally enrich the cluster from the protein-protein interaction network to obtain the hubgenes. Furthermore, we constructed Hubgene-chemical network, HubgenemicroRNA network, and Hubgene-transcription factor network of the top 10 obtained the protein-protein hubgenes based on interaction NetworkAnalyst[39] was used to build Hubgene-chemical network and Hubgenechemical network, and miRTarBase[40] was used to build Hubgene-microRNA network. Cytoscape[38] was used for visualization. 2.5 Immune subtype construction We calculated the immune cell infiltration levels using the ssGSEA function of the GSVA package to obtain the enrichment score for each immune-related cell type. Subtype classification was further constructed based on the enrichment score features of immune-related cell types using the ConsensusClusterPlus package[31]. Then individuals were clustered into corresponding clusters. The differentially expressed genes among clusters were analyzed using the *limma* package with a threshold of adjusted P < 0.05 and  $|\log_2 \text{Fold Change}| > 2$  and the ggplot2 package[26] was used to visualization. We further analyzed the difference and correlation between top 10 hubgenes and immune infiltration. CIBERSORT is a method for characterizing cell composition of complex tissues from their gene expression profiles[41]. We obtained immune cell infiltration matrix by CIBERSORT with P < 0.05 as threshold. The ggplot2 package[26] and corrplot package were used to visualization. We further analyzed the correlation between top 10 hubgenes and immune cells.

156 2.6 Hubgene subtype construction 157 Subtype classification was constructed based on the expression of top 10 hubgenes 158 using the Consensus Cluster Plus package [31]. Then individuals were clustered into 159 corresponding clusters. We further analyzed the expression of top 10 hubgenes in 160 corresponding clusters. 2.7 Experimental Validation 161 162 The 8-week-old C57BL/6J mice were obtained from Vital River (Beijing, China) and 163 all animal experiments were reviewed and approved by the Experimental Animal 164 Center of Zhengzhou University (Zhengzhou, China) (ZZU-LAC20220311[23]). We 165 conducted transverse aortic constriction (TAC) to build the myocardial hypertrophy 166 model[42]. A total of 12 male mice were divided into the Sham group (N = 6) and the 167 TAC group (N = 6). After four weeks of TAC, the mice were sacrificed after 168 transthoracic echocardiography for the following experiments. Histomorphological 169 changes in the heart were determined by HE and WGA staining according to our 170 previous protocol[43, 44]. The mRNA expression of atrial natriuretic peptide (Anp), 171 brain natriuretic peptide (Bnp), myosin heavy chain 7 (Myh7), Hnrnpc, Fmr1, and Fto 172 in the heart tissue was quantified by real-time quantitative polymerase chain reaction 173 assay according to our previous protocol[43, 44]. The primer sequences are listed in 174 Table S1. 175 176 2.8 Statistical analysis 177 The experimental data are expressed as the mean and standard deviation and were 178 analyzed by Prism (version 9.5.0, GraphPad, CA, USA) with a t test and one-way 179 analysis of variance if applicable. P < 0.05 was considered statistically significant. 180 All data processing and analysis were completed through R (version 4.1.0) with 181 independent Student t test, Mann Whitney U test (Wilcoxon rank sum test), Chi 182 square test or Fisher exact test, if applicable. All P < 0.05 bilaterally was considered 183 statistically significant.

184 3. Results

185

199

207

211

3.1 m6A-related regulators in HCM

We obtained 20 m6A-related regulators in HCM. Among them, there were 6 writers

187 (METTL3, ZC3H13, METTL14, CBLL1, WTAP, and RBM15), 2 erasers (FTO and

188 ALKBH5), and 12 readers (YTHDC1, YTHDC2, ELAVL1, YTHDF1, LRPPRC,

189 YTHDF2, FMR1, YTHDF3, HNRNPC, HNRNPA2B1, IGF2BP2, and IGF2BP3).

The chromosomal locations of 20 m6A-related regulators were shown in Figure 2A.

191 A total of 8 m6A-related regulators differentially expressed, YTHDC1, HNRNPC,

and FMR1 were up-regulated in HCM and YTHDC2, FTO, WTAP, IGF2BP2, and

193 IGF2BP3 were down-regulated in HCM (Figure 2B&C). Through linear regression

analysis, we found that the expression of CBLL1, ZC3H13, METTL3, and METTL14

was highly positively correlated with FTO (P < 0.05, < 0.0001, < 0.0001,and <

196 0.0001, respectively), the expression of RBM15 was highly negatively correlated with

197 FTO (P < 0.0001), and the expression of CBLL1 and METTL14 was highly

negatively correlated with ALKBH5 (P < 0.001 and < 0.01, respectively) (Figure 2D).

200 3.2 Random forest model and nomogram

201 In the training cohort, we build the random forest model (Figure 3A). FTO, FMR1,

202 IGF2BP3, YTHDC1, and IGF2BP2 were top 5 important m6A-related regulators in

203 HCM (Figure 3B). The residual plots in the training and validation cohorts were

shown in Figure 3C&D (P < 0.0001 and < 0.001, respectively). Moreover, The ROC

205 curves indicated that the model performed well (AUC = 1 and 0.86 in the training and

validation cohorts, respectively) (Figure 3E).

We constructed a nomogram based on top 5 important m6A-related regulators in

209 HCM (Figure 4A) and calibration curve, decision curve analysis, and ROC curve

showed that the performance of nomogram was acceptable (Figure 4B~D).

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

Correlation analysis showed that FMR1 and T cells follicular helper, FTO and B cells naïve, Monocytes, T cells CD8, T cells regulatory (Tregs), IGF2BP2 and Dendritic cells resting, T cells gamma delta, T cells regulatory (Tregs), IGF2BP3 and Dendritic cells activated, Dendritic cells resting, T cells gamma delta, YTHDC1 were strongly correlated with T cells CD8 (Figure 4-1). 3.3 m6A subtype construction When k = 2, the classification was reliable and stable (Figure 5A~F). Among 10 hubgenes, NFKB1, PSMC4, PSMA4, PSMA2, and PSMA6 were dys-regulated in ClusterA and ClusterB (P < 0.001, < 0.01, < 0.001, < 0.01, and < 0.001, respectively) (Figure 5). Therefore, we divided the samples into ClusterA and ClusterB. Further, we obtained 329 differentially expressed genes (154 genes were up-regulated and 175 genes were down-regulate) (Figure 5G&H). Through enrichment analysis of 329 differentially expressed genes, we found that homophilic cell adhesion via plasma membrane adhesion molecules, positive regulation of necrotic cell death, respiratory electron transport chain, glycosylation, necrotic cell death, regulation of necrotic cell death, energy derivation by oxidation of organic compounds, mitochondrial ATP synthesis coupled electron transport, cellular response to osmotic stress, and positive regulation of amino acid transport were enriched in biological process; endocytic vesicle lumen, autolysosome, respiratory chain complex, Golgi cis cisterna, haptoglobin-hemoglobin complex, mitochondrial respirasome, mitochondrial respiratory chain complex IV, hemoglobin complex, Golgi cisterna membrane, and ficolin-1-rich granule membrane were enriched in cellular component; Rac GTPase binding, fibronectin binding, inorganic anion intramolecular transmembrane activity, transporter transferase activity, phosphotransferases, haptoglobin binding, RAGE receptor binding, pre-mRNA intronic binding, copper ion binding, oxygen binding, and oxygen carrier activity, were enriched in molecular function (Figure 6A). Calcium signaling pathway,

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261262

263

264

265

266

267

268

Sphingolipid metabolism, Gastric acid secretion, Leukocyte transendothelial migration, Neuroactive ligand-receptor interaction, Malaria, and Proximal tubule bicarbonate reclamation were enriched in Kyoto Encyclopedia of Genes and Genomes (Figure 6B). Calcium signaling pathway and Leukocyte transendothelial migration were visualized in Figure 6C&D. Through gene set enrichment analysis, pathways related to infection, oxidative stress, immunity, and amino acid metabolism were enriched (Figure 6E). Through protein-protein interaction analysis of 329 differentially expressed genes, we obtained a network consisting of 143 genes and 184 connections (Figure 7A). Next, we got sub-networks consisting of the top 20 and 10 genes (Figure 7B&C). Furthermore, we constructed Hubgene-chemical network, Hubgene-microRNA network, and Hubgene-transcription factor network of the top 10 hubgenes. Hubgenechemical network included 574 nodes (10 hubgenes and 564 chemicals) and 837 edges (Figure 8A), Hubgene-microRNA network included 131 nodes (9 hubgenes and 121 microRNAs) and 132 edges (Figure 8B), Hubgene-transcription factor network included 181 nodes (10 hubgenes and 171 transcription factors) and 284 edges (Figure 8C). 3.4 Immune subtype construction When k = 2, the classification was reliable and stable (Figure 9A $\sim$ D). Therefore, we divided the samples into ImmuClusterA and ImmuClusterB. Further, we obtained 50 differentially expressed genes (15 genes were up-regulated and 35 genes were downregulated) (Figure 9E). Among top 10 hubgenes, NFKB1, PSMD10, and PSMA6 negatively correlated with most immune cell infiltration and PSMC4 and PSMA4 positively correlated with most immune cell infiltration (Figure 9F). Interestingly, NFKB1, PSMD10, PSMA6, PSMC4, and PSMA4 were dys-regulated in 269 ImmuClusterA and ImmuClusterB (P < 0.001, < 0.01, < 0.001, < 0.01, and < 0.01,270 respectively) (Figure 9G), suggesting these genes may be immune-related targets. 271 272 We used the CIBERSORT algorithm to analyze the proportion of immune subsets in 273 patients with HCM, and constructed a map of 22 immune cells in HCM (Figure 10A) 274 and the correlation of 22 immune cells (Figure 10B). We analyzed the correlation 275 between top 10 hubgenes and immune cells, and found that NFKB1 was negatively 276 correlated with CD8<sup>+</sup> T cells and T regulatory cells (Figure 10 C&D), PSMA4 was 277 negatively correlated with B naïve cells and positively correlated CD8<sup>+</sup> T cells 278 (Figure 10E&F), PSMA6 was negatively correlated with mast cells and T regulatory 279 cells (Figure 10 G&H), PSMC4 was positively correlated T follicular helper cells and 280 negatively correlated with T gamma delta cells (Figure 10 I&J), PSMD7 and PSMD8 281 were negatively correlated with T gamma delta cells (Figure 10 K&L) PSMD10 was 282 negatively correlated with and T regulatory cells (Figure 10 M). 283 284 3.5 Hubgene subtype construction 285 When k = 2, the classification was reliable and stable (Figure 11A $\sim$ E). We divided the 286 samples into GeneClusterA and GeneClusterB. And through principal component 287 analysis, it was found that the classification was significantly different (Figure 11F). 288 Among 10 hubgenes, NFKB1, PSMA4, and PSMA6 were dys-regulated between 289 GeneClusterA and GeneClusterB (P < 0.001, < 0.01, and < 0.001, respectively) 290 (Figure 11G). 291 292 3.6 Experimental Validation 293 294 Relative mRNA levels of hypertrophy marker genes (ANP, BNP, and MYH7) and 295 Hnrnpc, Fmr1, Fto in heart tissues from mice at four weeks after sham operations or 296 TAC surgery (n=6). For statistical analysis, nonparametric statistical analysis was 297 performed using the Mann-Whitney test for two groups.

## 4. Discussion

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

HCM is mainly caused by the mutations in sarcomere genes[45]. Relevant genetic testing has been recommended by guidelines and has promoted the diagnosis of HCM to a certain extent. However, more and more studies show that the clinical characteristics observed in patients with HCM is not all caused by abnormal sarcomeric proteins[2, 46, 47]. Therefore, it is necessary to explore alternative molecular mechanisms of HCM and identify more valuable biomarkers by utilizing contemporary methods to analyze biological complexity[48]. Here, we firstly identified 20 m6A-related regulators in HCM and constructed the m6A, immune, and hubgene subtypes. Finally, the key findings were validated the molecular biology experiments. m6A is required for the formation of a nuclear body mediated by phase separation that maintains mRNA stability[49]. YTHDC1 mediates export of methylated mRNA from the nucleus to the cytoplasm and knockdown of YTHDC1 results in an extended residence time for nuclear m6A-containing mRNA, with an accumulation of transcripts in the nucleus and accompanying depletion within the cytoplasm[50]. YTHDC2 is a powerful endogenous ferroptosis inducer and targets SLC3A2 and SLC7A11[51, 52]. HNRNPC is attributed to the function of controlling the endogenous double-stranded RNA and the downstream interferon response[53]. Sequence-specific mRNAs instruct FMR1-ribonucleoprotein granules to undergo a dynamic phase switch, thus contributing to maternal mRNA decay. FTO mediated the m6A level of LINC00022 and MALAT to promote the tumorigenesis[54, 55]. WTAP-guided m6A modification contributes to the progression of hepatocellular carcinoma via the HuR-ETS1-p21/p27 axis[56]. IGF2BP2/3 m6A promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling[57] and attenuates the detrimental effect of irradiation on lung adenocarcinoma[58]. Here, we found that these m6A-related regulators were differentially expressed in HCM. Moreover, we illustrated the correlations of certain m6A-related regulators. Then we

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

built the high-fidelity random forest model and used the top 5 important m6A-related regulators in HCM (namely FTO, FMR1, IGF2BP3, YTHDC1, and IGF2BP2) to construct the nomogram, which is a good predictor for the risk of HCM. According to the expression of these 5 m6A-related regulators, we constructed the m6A subtype. Based on the 329 differential genes of the two subtypes, we enriched many biological processes and signaling pathways known to be associated with HCM. Activation of CaMK-signaling pathway may be involved in the pathophysiology of HCM[59]. Posttranslational activation of the CaMKII pathway is specific to sarcomere mutationpositive HCM, whereas sarcoplasmic endoplasmic reticular calcium ATPase 2 abundance and sarcoplasmic reticulum Ca<sup>2+</sup> uptake are depressed in both sarcomere mutation-positive and -negative HCM[60]. HCM is characterized by enhanced oxidative stress, which achieves its highest values in the presence of LVOT obstruction in HCM patients[61] and reducing oxidative stress can be a viable therapeutic approach to attenuating the severity of cardiac dysfunction in HCM and prevent its progression[62]. Importantly, we also enriched oxidative stress-related signaling pathways. After protein-protein interaction of 329 differentially expressed genes, Hubgene-chemical network, Hubgene-microRNA network, and Hubgenetranscription factor network of the top 10 hubgenes among 329 differentially expressed genes were sequentially constructed, which not only provide ideas for the pathogenesis of HCM, but also give insights into the treatment of HCM. m6A is closely connected to immune cell infiltration[20, 21] and the immune system engage in the HCM mechanisms[22, 23]. After m6A subtype, we constructed immune subtype according to the immune cell infiltration levels. We demonstrated the correlation of some differential genes with immune cell infiltration and various immune cells, which further deepens the understanding of immunity in the occurrence and development of HCM. And then hubgene subtype classification was constructed based on the expression of top 10 hubgenes and NFKB1, PSMA4, and PSMA6 were dys-regulated between hubgene subtypes.

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

This study establishes a clinically accessible model for predicting HCM risk through bioinformatics analysis using transcriptome datasets of HCM patients and healthy controls, and furthers the understanding of the molecular mechanisms of m6A and immunity in HCM. Nonetheless, our study still has some limitations and inadequacies. Firstly, although we used different datasets for the analysis, because this was a reanalysis based on the existing data, we could not fully obtain more pathological, clinical and prognostic information of the dataset, which led us to build a risk model later, rather than provide more evidence for treatment or prognosis. In addition, we constructed different networks, which have a certain role in promoting the pathogenesis and clinical treatment of HCM. Although we have carried out biological experiments to verify important results, most of the results we obtained are based on computer analysis. Many basic experiments and clinical experiments are warranted to validate our findings. 5. Conclusion The systematic analysis of the transcriptional profiles of HCM and exploration of the potential underlying molecular mechanisms led to the identification of m6A, immune and hubgene subtype of HCM. Based on these, a risk assessment model of HCM was developed that brings a novel understanding to the current understanding of HCM. **Abbreviations Declarations** Ethics approval and consent to participate All animal experiment was conducted in accordance with the internationally accepted principles for laboratory animal use and care and was reviewed and approved by the Experimental Animal Center of Zhengzhou University (Zhengzhou, China) (ZZU-LAC20220311[23]). Our study is reported in accordance with the Animal Research: Reporting of in vivo Experiments guidelines.

- 382 Consent for publication
- 383 Not applicable.
- 384 Availability of data and materials
- 385 All data generated or analyzed during this study are included in this published article
- and its supplementary information files.
- 387 Competing interests
- 388 Not applicable.
- 389 Funding
- 390 This work was partly funded by.
- 391 Authors contributions
- 392 BL and NG conceived, designed, and planned the study. BL and NG acquired and
- analyzed the data. BL completed the experiments. BL and NG interpreted the results.
- 394 BL drafted the manuscript and NG contributed to the critical revision of the
- 395 manuscript. All authors read and approved the final manuscript.
- 396 Acknowledgments
- 397 We are grateful to all research scientists who participated in the aforementioned
- 398 databases.
- 399 References
- 400 1. Palandri C, Santini L, Argirò A, Margara F, Doste R, Bueno-Orovio A,
- 401 Olivotto I, Coppini R: Pharmacological Management of Hypertrophic
- 402 Cardiomyopathy: From Bench to Bedside. Drugs 2022, 82(8):889-912.
- 403 2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL,
- 404 Hung J, Joglar JA, Kantor P et al: 2020 AHA/ACC Guideline for the
- 405 Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy:
- 406 A Report of the American College of Cardiology/American Heart
- 407 Association Joint Committee on Clinical Practice Guidelines. Circulation
- 408 2020, **142**(25):e558-e631.
- 409 3. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P,
- 410 Hagege AA, Lafont A, Limongelli G, Mahrholdt H et al: 2014 ESC
- 411 Guidelines on diagnosis and management of hypertrophic
- 412 cardiomyopathy: the Task Force for the Diagnosis and Management of
- 413 Hypertrophic Cardiomyopathy of the European Society of Cardiology
- 414 **(ESC)**. European heart journal 2014, **35**(39):2733-2779.
- 415 4. Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron
- 416 BJ, Maron MS, Maron BA: Mechanism of Progressive Heart Failure and

- Significance of Pulmonary Hypertension in Obstructive Hypertrophic
- 418 **Cardiomyopathy**. *Circ Heart Fail* 2017, **10**(4):e003689.
- 419 5. Ommen SR, Semsarian C: Hypertrophic cardiomyopathy: a practical
- 420 **approach to guideline directed management**. *Lancet (London, England)*421 2021, **398**(10316):2102-2108.
- 422 6. Geisterfer-Lowrance AA, Christe M, Conner DA, Ingwall JS, Schoen FJ,
- 423 Seidman CE, Seidman JG: A mouse model of familial hypertrophic
- 424 **cardiomyopathy**. *Science* (*New York*, *NY*) 1996, **272**(5262):731-734.
- 425 7. Pagiatakis C, Di Mauro V: The Emerging Role of Epigenetics in
- Therapeutic Targeting of Cardiomyopathies. Int J Mol Sci 2021,
- **22**(16):8721.
- 428 8. Takeda Y, Demura M, Yoneda T, Takeda Y: DNA Methylation of the
- 429 Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene,
- 430 **CYP11B2 in Cardiovascular Diseases**. *Int J Mol Sci* 2021, **22**(9):4587.
- 431 9. Liu C, Gu L, Deng W-J, Meng Q-C, Li N, Dai G, Yu S, Fang H: N6-
- 432 Methyladenosine RNA Methylation in Cardiovascular Diseases. Frontiers
- 433 in cardiovascular medicine 2022, **9**:887838.
- 434 10. Chien C-S, Li JY-S, Chien Y, Wang M-L, Yarmishyn AA, Tsai P-H, Juan C-
- C, Nguyen P, Cheng H-M, Huo T-I et al: METTL3-dependent N(6)-
- 436 methyladenosine RNA modification mediates the atherogenic
- inflammatory cascades in vascular endothelium. Proc Natl Acad Sci U S A
- 438 2021, **118**(7):e2025070118.
- 439 11. Li B-C, Zhang T, Liu M-X, Cui Z, Zhang Y-H, Liu M, Liu Y, Sun Y, Li M,
- Tian Y et al: RNA N(6)-methyladenosine modulates endothelial
- atherogenic responses to disturbed flow in mice. *eLife* 2022, **11**:e69906.
- 442 12. Su X, Shen Y, Jin Y, Kim I-M, Weintraub NL, Tang Y: Aging-Associated
- Differences in Epitranscriptomic m6A Regulation in Response to Acute
- 444 Cardiac Ischemia/Reperfusion Injury in Female Mice. Front Pharmacol
- 445 2021, **12**:654316.
- 446 13. Mo X-B, Lei S-F, Zhang Y-H, Zhang H: Examination of the associations
- between m(6)A-associated single-nucleotide polymorphisms and blood
- 448 **pressure**. Hypertension research: official journal of the Japanese Society of
- 449 *Hypertension* 2019, **42**(10):1582-1589.
- 450 14. Cheng P-K, Han H-K, Chen F-L, Cheng L, Ma C, Huang H, Chen C, Li H,
- 451 Cai H, Huang H et al: Amelioration of acute myocardial infarction injury
- 452 through targeted ferritin nanocages loaded with an ALKBH5 inhibitor.
- 453 *Acta biomaterialia* 2022, **140**:481-491.
- 454 15. Qian B-H, Wang P, Zhang D-H, Wu L: m6A modification promotes miR-
- 455 133a repression during cardiac development and hypertrophy via
- 456 **IGF2BP2**. Cell Death Discov 2021, **7**:157-157.
- 457 16. Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Agarwal N, Jha
- 458 D, Zhang S, Kohlbrenner E, Chepurko E et al: FTO-Dependent N(6)-

- Methyladenosine Regulates Cardiac Function During Remodeling and Repair. Circulation 2019, 139(4):518-532.
- 461 17. Zhang B-J, Xu Y-M, Cui X-T, Jiang H, Luo W, Weng X, Wang Y, Zhao Y,
- Sun A, Ge J: Alteration of m6A RNA Methylation in Heart Failure With
- 463 Preserved Ejection Fraction. Frontiers in cardiovascular medicine 2021,
  464 8:647806.
- 465 18. Shulman Z, Stern-Ginossar N: The RNA modification N(6)-
- methyladenosine as a novel regulator of the immune system. Nature
- 467 immunology 2020, **21**(5):501-512.
- 468 19. Wang Y-N, Yu C-Y, Jin H-Z: RNA N(6)-Methyladenosine Modifications
- and the Immune Response. Journal of immunology research 2020,
- **2020**:6327614.
- 471 20. Liang C-Z, Wang S, Zhang M, Li T: **Diagnosis, clustering, and immune cell**
- infiltration analysis of m6A-related genes in patients with acute
- **myocardial infarction-a bioinformatics analysis**. *Journal of thoracic disease* 2022, **14**(5):1607-1619.
- 475 21. Yin F-X, Zhang H, Guo P-P, Wu Y, Zhao X, Li F, Bian C, Chen C, Han Y,
- 476 Liu K: Comprehensive Analysis of Key m6A Modification Related Genes
- and Immune Infiltrates in Human Aortic Dissection. Frontiers in
- 478 cardiovascular medicine 2022, **9**:831561.
- 479 22. Kardaszewicz B, Rogala E, Tendera M, Kardaszewicz P, Jarzab J:
- 480 Circulating immune complexes in hypertrophic cardiomyopathy and
- 481 **ischemic heart disease**. *Kardiologia polska* 1991, **34**(1):21-24.
- 482 23. Lüscher TF: An update on cardiomyopathies: immune-mediated diseases,
- sarcoidosis, and peripartum and hypertrophic cardiomyopathies during
- **pregnancy**. *European heart journal* 2017, **38**(35):2635-2638.
- 485 24. Wang Z-Q, Ruan H-Y, Li L-Y, Wei X, Zhu Y, Wei J, Chen X, He S:
- 486 Assessing the relationship between systemic immune-inflammation index
- and mortality in patients with hypertrophic cardiomyopathy. Upsala
- 488 journal of medical sciences 2021, **126**.
- 489 25. Maron BA, Wang R-S, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O,
- 490 Huggins GS, Samokhin AO, Oldham WM, Aguib Y et al: Individualized
- interactomes for network-based precision medicine in hypertrophic
- 492 cardiomyopathy with implications for other clinical pathophenotypes. *Nat*
- 493 *Commun* 2021, **12**(1):873-873.
- 494 26. Zhou J-G, Liang B, Jin S-H, Liao H-L, Du G-B, Cheng L, Ma H, Gaipl US:
- 495 Development and Validation of an RNA-Seq-Based Prognostic Signature
- 496 in Neuroblastoma. Front Oncol 2019, 9:1361.
- 497 27. Zhou J-G, Liang B, Liu J-G, Jin S-H, He S-S, Frey B, Gu N, Fietkau R, Hecht
- 498 M, Ma H et al: Identification of 15 lncRNAs Signature for Predicting
- 499 Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1
- 500 **Monotherapy**. *Cells* 2021, **10**(5):977.

- 501 28. Kainuma A, Ning Y, Kurlansky PA, Wang AS, Latif F, Sayer GT, Uriel N,
- Kaku Y, Naka Y, Takeda K: Predictors of one-year outcome after cardiac
- re-transplantation: Machine learning analysis. Clinical transplantation 2022:e14761.
- 505 29. Lu W-C, Chen H, Liang B, Ou C-P, Zhang M, Yue Q, Xie J: Integrative
- 506 Analyses and Verification of the Expression and Prognostic Significance
- for RCN1 in Glioblastoma Multiforme. Front Mol Biosci 2021, 8:736947.
- 508 30. Zhang M-W, Chen H, Liang B, Wang X-Z, Gu N, Xue F-Q, Yue Q-Y, Zhang
- 509 O-Y, Hong J-S: Prognostic Value of mRNAsi/Corrected mRNAsi
- 510 Calculated by the One-Class Logistic Regression Machine-Learning
- Algorithm in Glioblastoma Within Multiple Datasets. Front Mol Biosci 2021, 8:777921.
- 513 31. Wilkerson MD, Hayes DN: ConsensusClusterPlus: a class discovery tool
- with confidence assessments and item tracking. Bioinformatics 2010,
- **26**(12):1572-1573.
- 516 32. Yu G-C, Wang L-G, Han Y, He Q-Y: clusterProfiler: an R package for
- comparing biological themes among gene clusters. Omics: a journal of
- 518 integrative biology 2012, **16**(5):284-287.
- 519 33. Luo W-J, Brouwer C: Pathview: an R/Bioconductor package for pathway-
- based data integration and visualization. *Bioinformatics* 2013, **29**(14):1830-
- 521 1831.
- 522 34. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P:
- The Molecular Signatures Database (MSigDB) hallmark gene set
- 524 **collection**. *Cell Syst* 2015, **1**(6):417-425.
- 525 35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
- Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment
- 527 analysis: a knowledge-based approach for interpreting genome-wide
- 528 **expression profiles.** *Proc Natl Acad Sci U S A* 2005, **102**(43):15545-15550.
- 529 36. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva
- 530 NT, Legeay M, Fang T, Bork P et al: The STRING database in 2021:
- 531 customizable protein-protein networks, and functional characterization of
- **user-uploaded gene/measurement sets.** Nucleic acids research 2021,
- 533 **49**(D1):D605-D612.
- 534 37. Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y: cytoHubba:
- identifying hub objects and sub-networks from complex interactome.
- 536 *BMC systems biology* 2014, **8 Suppl 4**(Suppl 4):S11.
- 537 38. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
- Schwikowski B, Ideker T: Cytoscape: a software environment for
- integrated models of biomolecular interaction networks. Genome Res 2003,
- **13**(11):2498-2504.
- 541 39. Zhou G-Y, Soufan O, Ewald J, Hancock REW, Basu N, Xia J-G:
- 542 NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene

- expression profiling and meta-analysis. Nucleic acids research 2019, 47(W1):W234-w241.
- 545 40. Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, Tang Y,
- Chen Y-G, Jin C-N, Yu Y et al: miRTarBase 2020: updates to the
- experimentally validated microRNA-target interaction database. *Nucleic* acids research 2020, **48**(D1):D148-D154.
- 549 41. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD,
- Diehn M, Alizadeh AA: Robust enumeration of cell subsets from tissue
- **expression profiles**. *Nat Methods* 2015, **12**(5):453-457.
- 552 42. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ,
- Ross J, Jr., Chien KR: Segregation of atrial-specific and inducible
- expression of an atrial natriuretic factor transgene in an in vivo murine
- model of cardiac hypertrophy. Proc Natl Acad Sci U S A 1991, 88(18):8277 8281.
- 557 43. Liang B, Zhang X-X, Li R, Gu N: Guanxin V protects against ventricular
- remodeling after acute myocardial infarction through the interaction of
- **TGF-β1 and Vimentin**. *Phytomedicine* 2022, **95**:153866.
- 560 44. Liang B, Zhang X-X, Li R, Zhu Y-C, Tian X-J, Gu N: Guanxin V alleviates
- acute myocardial infarction by restraining oxidative stress damage,
- apoptosis, and fibrosis through the TGF-β1 signalling pathway.
- *Phytomedicine* 2022, **100**:154077.
- 564 45. van der Velde N, Huurman R, Hassing HC, Budde RPJ, van Slegtenhorst MA,
- Verhagen JMA, Schinkel AFL, Michels M, Hirsch A: Novel Morphological
- Features on CMR for the Prediction of Pathogenic Sarcomere Gene
- Variants in Subjects Without Hypertrophic Cardiomyopathy. Frontiers in cardiovascular medicine 2021, 8:727405.
- 569 46. Bos JM, Will ML, Gersh BJ, Kruisselbrink TM, Ommen SR, Ackerman MJ:
- 570 Characterization of a phenotype-based genetic test prediction score for
- 571 unrelated patients with hypertrophic cardiomyopathy. Mayo Clinic
- *proceedings* 2014, **89**(6):727-737.
- 573 47. Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF,
- 574 Appelbaum E. Desvigne-Nickens P. DiMarco JP. Friedrich MG et al: **Distinct**
- 575 Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM
- Registry. Journal of the American College of Cardiology 2019, **74**(19):2333-
- 577 2345.
- 578 48. Zheng X-F, Liu G-Y, Huang R-N: **Identification and Verification of**
- 579 Feature Immune-Related Genes in Patients With Hypertrophic
- Cardiomyopathy Based on Bioinformatics Analyses. Frontiers in
- 581 *cardiovascular medicine* 2021, **8**:752559.
- 582 49. Cheng Y-M, Xie W, Pickering BF, Chu KL, Savino AM, Yang X, Luo H,
- Nguyen DT, Mo S, Barin E et al: N(6)-Methyladenosine on mRNA

- facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer cell 2021, **39**(7):958-972.e958.
- 586 50. Roundtree IA, Luo G-Z, Zhang Z-J, Wang X, Zhou T, Cui Y, Sha J, Huang X,
- Guerrero L, Xie P *et al*: **YTHDC1 mediates nuclear export of N(6)**methyladenosine methylated mRNAs. *eLife* 2017, **6**:e31311.
- 589 51. Ma L-F, Chen T-X, Zhang X, Miao Y, Tian X, Yu K, Xu X, Niu Y, Guo S,
- Zhang C et al: The m(6)A reader YTHDC2 inhibits lung adenocarcinoma
- 591 tumorigenesis by suppressing SLC7A11-dependent antioxidant function.
- 592 *Redox biology* 2021, **38**:101801.
- 593 52. Ma L-F, Zhang X, Yu K-K, Xu X, Chen T, Shi Y, Wang Y, Qiu S, Guo S, Cui
- J et al: Targeting SLC3A2 subunit of system X(C)(-) is essential for m(6)A
- reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma. Free radical biology & medicine 2021, 168:25-43.
- 597 53. Wu Y-S, Zhao W-W, Liu Y, Tan X, Li X, Zou Q, Xiao Z, Xu H, Wang Y,
- Yang X: Function of HNRNPC in breast cancer cells by controlling the
- 599 **dsRNA-induced interferon response**. The EMBO journal 2018,
- **37**(23):e99017.
- 601 54. Cui Y-B, Zhang C-Y, Ma S-S, Li Z, Wang W, Li Y, Ma Y, Fang J, Wang Y,
- Cao W et al: RNA m6A demethylase FTO-mediated epigenetic up-
- regulation of LINC00022 promotes tumorigenesis in esophageal
- **squamous cell carcinoma**. *Journal of experimental & clinical cancer* 605 *research : CR* 2021, **40**(1):294.
- 55. Tao L, Mu X-Y, Chen H-G, Jin D, Zhang R, Zhao Y, Fan J, Cao M, Zhou Z:
- FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clinical and translational medicine 2021, 11(2):e310.
- 609 56. Chen Y-H, Peng C-H, Chen J-R, Chen D, Yang B, He B, Hu W, Zhang Y, Liu
- H, Dai L et al: WTAP facilitates progression of hepatocellular carcinoma
- via m6A-HuR-dependent epigenetic silencing of ETS1. Molecular cancer
- 612 2019, **18**(1):127.
- 613 57. Liu X, He H-J, Zhang F-W, Hu X, Bi F, Li K, Yu H, Zhao Y, Teng X, Li J et
- al: m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation
- promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and
- 616 **ERK1/2 signaling**. Cell death & disease 2022, **13**(5):483.
- 617 58. Hao C-C, Xu C-Y, Zhao X-Y, Luo J-N, Wang G, Zhao L-H, Ge X, Ge X-F:
- 618 Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the
- detrimental effect of irradiation on lung adenocarcinoma. Journal of
- 620 experimental & clinical cancer research : CR 2020, **39**(1):256.
- 621 59. Chen P, Li Z, Nie J, Wang H, Yu B, Wen Z, Sun Y, Shi X, Jin L, Wang D-W:
- 622 MYH7B variants cause hypertrophic cardiomyopathy by activating the
- 623 CaMK-signaling pathway. Science China Life sciences 2020, 63(9):1347-
- 624 1362.

- 625 60. Helms AS, Alvarado FJ, Yob J, Tang VT, Pagani F, Russell MW, Valdivia
- 626 HH, Day SM: Genotype-Dependent and -Independent Calcium Signaling
- **Dysregulation in Human Hypertrophic Cardiomyopathy**. Circulation 2016,
- 628 **134**(22):1738-1748.
- 629 61. Dimitrow PP, Undas A, Wołkow P, Tracz W, Dubiel JS: Enhanced oxidative
- stress in hypertrophic cardiomyopathy. Pharmacological reports: PR 2009,
- **63**1 **61**(3):491-495.
- 632 62. Hassoun R, Budde H, Zhazykbayeva S, Herwig M, Sieme M, Delalat S,
- Mostafi N, Gömöri K, Tangos M, Jarkas M et al: Stress activated signalling
- 634 impaired protein quality control pathways in human hypertrophic
- cardiomyopathy. *International journal of cardiology* 2021, **344**:160-169.
- 636 Tables

- Table 1. Details of datasets.
- 639 Figure legends
- Figure 1. Flow chart of this study.
- Figure 2. The landscape of m6A-related regulators in HCM. A. The chromosomal
- locations of 20 m6A-related regulators. B. Heatmap of expression of 20 m6A-related
- regulators. C. Histogram of expression of 20 m6A-related regulators. \*P < 0.05, \*\*P
- < 0.01, \*\*\*P < 0.001. D. The correlation between writers and erasers.
- 645 Figure 3. Random forest model construction. A. Model was built in the training cohort.
- B. Importance of m6A-related regulators based on the model. C. Residual plot
- showing the distribution of residuals in the training cohort. D. Residual plot showing
- 648 the distribution of residuals in the validation cohort. E. The ROC curves showing the
- accuracy of the model in the training and validation cohorts.
- 650 Figure 4. Construction of the nomogram. A. Construction of the nomogram based on
- 651 top 5 important m6A-related regulators in HCM. B. Calibration curve. C. decision
- curve analysis. D. ROC curve.
- Figure 4-1. Correlation between top 5 candidate m6A regulators and immune-related
- cell types.

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

Figure 5. m6A subtype construction based on the expression of top 5 m6A-related regulators. A. Matrix heatmap for k = 2. B. Matrix heatmap for k = 3. C. Matrix heatmap for k = 4. D. Consistent cumulative distribution function plot. This figure allows a user to determine at what number of clusters, k, the cumulative distribution function reaches an approximate maximum, thus consensus and cluster con dence is at a maximum at this k. E. Delta area plot. The delta area score (y-axis) indicates the relative increase in cluster stability. F. Tracking plot. This plot provides a view of item cluster membership across different k and enables a user to track the history of clusters relative to earlier clusters. G. Heatmap for differentially expressed genes. H. Volcano plot for differentially expressed genes. I. Difference analysis of top 10 hubgene in m6A subtype classification. Figure 6. Functional enrichment of 329 differentially expressed genes. A. Top 10 gene ontology terms. B. Top 7 Kyoto Encyclopedia of Genes and Genomes terms. C. Visualization of Calcium signaling pathway. D. Visualization of Leukocyte transendothelial migration. E. Gene set enrichment analysis terms. Figure 7. Protein-protein interaction network. A. Protein-protein interaction network among those genes with a score greater than 0.6. B. Protein-protein interaction network of top 20 hubgenes. C. Protein-protein interaction network of top 10 hubgenes. Figure 8. Networks of the top 10 hubgenes. A. Hubgene-chemical network. B. Hubgene-microRNA network. C. Hubgene-transcription factor network. Figure 9. Immune subtype construction. A. Matrix heatmap for k = 2. B. Matrix heatmap for k = 3. C. Consistent cumulative distribution function plot. This figure allows a user to determine at what number of clusters, k, the cumulative distribution function reaches an approximate maximum, thus consensus and cluster con dence is at a maximum at this k. D. Delta area plot. The delta area score (y-axis) indicates the relative increase in cluster stability. E. Heatmap for differentially expressed genes. F.

682 The correlation between top 10 hubgenes and immune-related cell types. G. 683 Histogram of expression of top 10 hubgenes. \*\*P < 0.01, \*\*\*P < 0.001. 684 Figure 10. CIBERSORT immune cell infiltration analysis and correlation analysis 685 between hubgene and immune cells. A. Barplot showing the proportions of 22 686 immune cells in a sepsis sample. The column in the figure is a sample. B. Correlation 687 heat map of 22 immune cells infiltration. Blue indicated positive correlation, red 688 indicated negative correlation, the darker the color, the stronger the correlation. C. 689 The correlation between NFKB1 and CD8<sup>+</sup> T cells. D. The correlation between 690 NFKB1 and T regulatory cells. E. The correlation between PSMA4 and B naïve cells. 691 F. The correlation between PSMA4 and CD8<sup>+</sup> T cells. G. The correlation between 692 PSMA6 and mast cells. H. The correlation between PSMA6 and T regulatory cells. I. 693 The correlation between PSMC4 and T follicular helper cells. J. The correlation 694 between PSMC4 and T gamma delta cells. K. The correlation between PSMD7 and T 695 gamma delta cells. L. The correlation between PSMD8 and T gamma delta cells. M. 696 The correlation between PSMD10 and T regulatory cells. 697 Figure 11. Hubgene subtype construction. A. Matrix heatmap for k = 2. B. Matrix 698 heatmap for k = 3. C. Consistent cumulative distribution function plot. This figure 699 allows a user to determine at what number of clusters, k, the cumulative distribution 700 function reaches an approximate maximum, thus consensus and cluster con dence is at 701 a maximum at this k. D. Delta area plot. The delta area score (y-axis) indicates the 702 relative increase in cluster stability. E. Tracking plot. This plot provides a view of 703 item cluster membership across different k and enables a user to track the history of 704 clusters relative to earlier clusters. F. Principal component analysis. G. Difference 705 analysis of top 10 hubgenes in hubgene subtype classification. 706

## Additional files

707

708 Table S1. Primer sequences.

- 709 Figure S1. Datasets collation. A. All samples were pooled before removing batch
- 710 effects. B. All samples were pooled after removing batch effects.



































